116 results on '"Lottenburger, T"'
Search Results
2. Galectin‐3 is Persistently Increased in Early Rheumatoid Arthritis (RA) and Associates with Anti‐CCP Seropositivity and MRI Bone Lesions, While Early Fibrosis Markers Correlate with Disease Activity
3. Within-day variation and influence of physical exercise on circulating Galectin-3 in patients with rheumatoid arthritis and healthy individuals
4. Circadian rhythm and the influence of physical activity on circulating surfactant protein D in early and long-standing rheumatoid arthritis
5. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial
6. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)
7. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study
8. Biological Variation in Circulating Levels of Mannan-Binding Lectin (MBL) and MBL-Associated Serine Protease-2 and the Influence of Age, Gender and Physical Exercise
9. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial
10. AB1420-HPR Patient delay in rheumatoid arthritis. a survey on symptom interpretation before first visit to general practitioner
11. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials
12. Changes in multi-biomarker disease activity (MBDA) score correlate with changes in established disease activity measurements in patients with early RA from the opera study
13. FRI0641 Wrist inflammation as assessed by magnetic resonance imaging is associated with patient-reported physical impairment, global disease activity and pain in early rheumatoid arthritis: long-term results from two randomized controlled trials
14. Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)
15. Effect of Methotrexate and Intra-Articular Betamethasone with or Without Additional Cyclosporine on Magnetic Resonance Imaging (MRI)-Determined Inflammatory and Destructive Changes in Very Early Rheumatoid Arthritis – Results from a 24-Months' Randomised Double Blind Placebo Controlled Trial
16. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.
17. FRI0067 Changes in Multi-Biomarker Disease Activity (MBDA) Score Correlate with Changes in Established Disease Activity Measurements in Patients with Early Ra from The Opera Study
18. FRI0547 Magnetic Resonance Imaging Joint Space Narrowing Is An Independent Predictor of Radiographic and MRI Damage Progression in Patients with Early Rheumatoid Arthritis: Table 1
19. FRI0535 Hand Bone Loss in Early Rheumatoid Arthritis Is Independent of Adalimumab Treatment. A Substudy of The Optimized Treatment Algorithm in Early RA (Opera) Trial
20. FRI0607 Effect of Methotrexate and Intra-Articular Betamethasone with or Without Additional Cyclosporine on Magnetic Resonance Imaging (MRI)-Determined Inflammatory and Destructive Changes in Very Early Rheumatoid Arthritis – Results from a 24-Months' Randomised Double Blind Placebo Controlled Trial
21. Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1
22. Is it possible to stop radiographic progression with conventional treatment in early rheumatoid arthritis?:2 years results from the CIMESTRA study
23. MRI Bone Oedema is the Strongest Predictor of Subsequent Radiographic Progression in Early RA. Results from a 2 Year Randomized Controlled Trial (CIMESTRA)
24. Combination treatment with methotrexate, cyclosporine, and intraarticularbetamethasone compared with methotrexate and intraarticular betamethasone inearly active rheumatoid arthritis: an investigator-initiated, multicenter,randomized, double-blind, parallel-group, placebo-controlled study
25. Plasma IL-6 in early rheumatoid arthritis is associated with disease activity, joint destruction, and treatment response
26. Plasma level of CXC-chemokine CXCL12 is increased in rheumatoid arthritis andis independent of disease activity and methotrexate treatment
27. Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA).
28. MRI is more sensitive to change of structural joint damage in early rheumatoid arthritis than X-ray [204]
29. Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis
30. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression
31. THU0212 Improved Remission Rates Acquired by Adding Adalimumab to Methotrexate and Intraarticular Glucocorticoid Cannot be Maintained after Withdrawal of Adalimumab. A 2-Year Investigator Initiated Randomised, Controlled Study on Early Rheumatoid Arthritis
32. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
33. Periarticular and generalised bone loss in patients with early rheumatoid arthritis (ERA). Influence of alendronate (AL) and glucocorticoid treatment, and disease activity
34. Diurnal variation of connective tissue metabolites in early and long-standing rheumatoid arthritis and in healthy individuals
35. Circadian rhythm and the influence of physical activity on circulating surfactant protein D in early and long-standing rheumatoid arthritis
36. Circadian pattern and the effect of standardized physical exercise on procollagen IIA N-peptide (PIIANP) in rheumatoid arthritis at different stages and in healthy individuals
37. Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis.
38. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.
39. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial.
40. Circadian pattern and the effect of standardized physical exercise on procollagen IIA N-peptide (PIIANP) in rheumatoid arthritis at different stages and in healthy individuals.
41. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study.
42. Wrist inflammation as assessed by magnetic resonance imaging is associated with patient-reported physical impairment, global disease activity and pain in early rheumatoid arthritis: long-term results from two randomized controlled trials
43. Plasma level of CXC-chemokine CXCL12 is increased in rheumatoid arthritis and is independent of disease activity and methotrexate treatment
44. Continuous excellent treatment response to aggressive combination therapy in early rheumatoid arthritis. Year two results from the Cimestra study, an investigator-initiated, randomised, controlled, double-blinded study of methotrexate, intraarticular corticosteroid and cyclosporine or placebo-cyclosporine
45. Circulating connective tissue metabolites in very early rheumatoid arthritis
46. Differential association of the N-propeptide of collagen IIA (PIIANP) and collagen II C-telopeptide (CTX-II) with synovitis and erosions in early and longstanding rheumatoid arthritis
47. Patients with active, early rheumatoid ahthhitis had increased plasma-cxcl12, independent of disease activity and response to DMARD-TREATMENT
48. HAND BONE LOSS IN EARLY RHEUMATOID ARTHRITIS IS INDEPENDENT OF ADALIMUMAB TREATMENT. A SUBSTUDY OF THE OPTIMIZED TREATMENT ALGORITHM IN EARLY RA (OPERA) TRIAL
49. Associations between anti-CCP, shared epitope and erosive disease at onset of rheumatoid arthritis are dominant in smoking patients
50. Circadian, Week-to-Week, and Physical Exercise-Induced Variation of Serum Microfibrillar-Associated Protein 4.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.